Cenegermin is a medication used in the management of neurotrophic keratitis. It is in the recombinant human nerve growth factor (rhNGF) class of medications. This activity describes the FDA-approved indications, action, and contraindications for cenegermin as a valuable agent in treating neurotrophic keratitis. In addition, this activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions ) pertinent for members of the interprofessional team in the management of patients with neurotrophic keratitis. It also provides information for clinicians on managing toxicity if an overdose has resulted while administering cenegermin.

**Objectives:**
- Identify the indications for cenegermin therapy.
- Describe the mechanism of action of cenegermin.

- Review the proper administration of cenegermin ophthalmic solution.
- Summarize the risks associated with initiating cenegermin therapy.